RxDoctor Payments Data

Colleen Hanley, MD

Clinical Cardiac Electrophysiology · Wynnewood, PANPI 1326298159

Payments from drug & device makers

$650in general payments, 2019–2025

Across 19 payments — averaging $34.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$281
  • Biosense Webster, Inc.$177
  • Abbott$65
  • Acist Medical Systems, Inc.$43
  • Atricure, Inc.$24
  • Chiesi USA, Inc.$17
  • plus $43 from 3 others

What the payments were for

  • Food & beverage$650100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$650 in reported general payments places this provider in the 5th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

See all clinical cardiac electrophysiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$249,011
Medicare patients
1,354
Services billed
4,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban796$927,778
XareltoRivaroxaban269$322,052
Dofetilide152$33,210
EntrestoSacubitril/Valsartan15$25,028
CorlanorIvabradine Hcl11$13,276
Metoprolol Succinate572$12,768
Dabigatran EtexilateDabigatran Etexilate Mesylate19$8,816
Amiodarone Hcl283$7,300
Diltiazem 24hr Er (Cd)Diltiazem Hcl158$6,668
Flecainide Acetate128$6,347
SotalolSotalol Hcl172$4,304
Atorvastatin Calcium119$1,627
Carvedilol125$1,602
Mexiletine Hcl12$1,178
Metoprolol Tartrate77$959

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenCorlanor$15$13,27611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

Other clinical cardiac electrophysiology in Wynnewood

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →